perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300140;](https://doi.org/10.1101/2023.12.22.23300140) this version posted December 26, 2023. The copyright holder for this

#### It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

## **Toward Precision Medicine in Aortopathies: Genetic Insights from a Brazilian Cohort**

- **Through Targeted Next-Generation Sequencing**
- 

4 Juliana R. Ferreira,<sup>1</sup> Julia P. Perreira,<sup>1</sup> Anna Paula A. Botelho,<sup>1</sup> Daniele N. Aprijo,<sup>2</sup> Marcelo

- 5 M. Melo,<sup>1</sup> Helena C. V. Rey,<sup>1</sup> Glauber M Dias<sup>2</sup>
- 
- 1- Instituto Nacional de Cardiologia, Rio de Janeiro, RJ, zip code 22240-002, Brazil
- 2- Laboratório de Biologia Celular e Tecidual, Universidade Estadual do Norte Fluminense
- Darcy Ribeiro, Campos dos Goytacazes, RJ, zip code 28013-602, Brazil.
- 

# **Corresponding author:**

Glauber M Dias

[glauber@uenf.br](mailto:glauber@uenf.br)

# **ABSTRACT**

 Thoracic aortic diseases (or aortopathies) result from complex interactions between genetic and hemodynamic factors. Often clinically silent, these diseases can lead to lethal complications like aortic dissection or rupture. This study focused on a Brazilian cohort of 79 individuals with thoracic aortic diseases, exploring genetic factors through targeted next- generation sequencing (tNGS) of 15 priority genes. The majority of individuals had non- syndromic aortopathy, with eight diagnosed with Marfan syndrome (MFS). Pathogenic or likely pathogenic variants (PV/LPV) were found in five genes, including FBN1, ACTA2, TGFBR2, MYLK, and SMAD3. Notably, novel variants in FBN1 were identified, contributing to Marfan-like phenotypes. The diagnostic yield for isolated aortopathies was 7.1%, rising to 55.5% for syndromic cases. Variants of uncertain significance (VUS) were identified, emphasizing the need for further research and familial investigations to refine variant classifications. This study provides valuable insights into the genetic landscape of aortopathies in Brazil, aiding early diagnosis and personalized management.

- 
- 

 **Keywords:** Aortic Aneurysm Thoracic, Fibrilin-1, Aneurism dissecting, Genetic testing, High-Throughput nucleotide sequencing

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300140;](https://doi.org/10.1101/2023.12.22.23300140) this version posted December 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### **INTRODUCTION**

 Aortopathies are diseases that affect the aortic artery and can occur either as an isolated characteristic or as part of a syndromic condition. Their development is linked to a complex interplay of genetic and hemodynamic factors. It is a clinically silent disease with a natural history of lethality, progressing to aortic dissection or rupture, where half of the patients die before reaching emergency services (1,2). The Centers for Disease Control and Prevention (CDC) reports that aortic aneurysms (thoracic and abdominal) are the 15th leading cause of death in individuals over 55 years old and the 19th leading cause of death overall (3). In Brazil, we can observe that the average annual mortality was 12,820 deaths due to aortic diseases, with a total of 128,204 deaths in the last 10 years and a mortality rate of 5.89 (4).

 Thoracic aorta diseases (TAD) can be associated with inherited genetic alterations, whereas those affecting the abdominal aorta are more commonly of degenerative origin and related to age and/or risk factors such as hypertension, smoking, dyslipidemia, and gender (5). Hereditary thoracic aortic diseases (HTAD) are characterized by progressive enlargement of the ascending aorta that predisposes to acute dissections (familial thoracic aortic aneurisms /dissections) (6). HTAD can be divided into syndromic and non-syndromic types. Among syndromic TADs, Marfan syndrome (MFS) is the primary type, followed by Loeys-Dietz syndrome (LDS) and Ehlers-Danlos syndrome (EDS), as well as other rarer conditions (7). However, these syndromes contribute to only approximately 5% of all TAD cases, while non-syndromic thoracic aortic diseases (NS-TAD) account for 95% of cases and are further divided into sporadic and familial forms (8).

 The genetic factors associated with TADs are inherited as monogenic mutations with an autosomal dominant inheritance pattern (9). Detection of a pathogenic mutation is useful for identifying an individual at risk of a potentially lethal aortic acute event (10). The known genes implicated in this process encode members of the TGFβ signaling pathway (TGFBR1, TGFBR2, TGFB2, SMAD3), components of the aortic wall extracellular matrix's structure and integrity (FBN1, COL3A1, LOX); or those affecting the function of smooth muscle cells, including actin (ACTA2), myosin (MYH11), myosin light chain kinase (MYLK), and protein kinase cGMP-dependent 1 (PRKG1) (11,12).

 The priority genes for TAD can be used to target research and diagnostic panels for aortopathies (13). However, for NS-TADs, the detection rate of variants in these genes is approximately 20-30% (7,10), suggesting the involvement of other mechanisms (genetic or non-genetic) in the pathophysiology. In Brazil, the frequency or incidence of variants in NS- TADs is unknown. We selected a cohort of 79 individuals with isolated and syndromic TADs from Brazil for genetic evaluation through NGS using a targeted gene panel. Here, we report the findings of the genetic screening of a Brazilian cohort of aortopathies.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300140;](https://doi.org/10.1101/2023.12.22.23300140) this version posted December 26, 2023. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### **SUBJECTS AND METHODS**

### *Study Population:*

 Patients diagnosed with thoracic aortic aneurysm (TAA), aortic dissection, and aortic coarctation before the age of 60, who were under the care of a quaternary cardiology center in Brazil, were recruited for this study. Inclusion criteria encompassed patients with suspected or confirmed clinical diagnosis of syndromic and non-syndromic aortopathies, all of whom were below 60 years of age (y) at the time of diagnosis. Patients with or without a family history of aortopathies, as well as those clinically suspected of having MFS, LDS and EDS were considered. Exclusion criteria included other causes of aortopathies such as familial dyslipidemia, syphilis, autoimmune and inflammatory diseases, and trauma. A total of 358 patients were evaluated, out of which 103 met the inclusion criteria. After assessing the exclusion criteria, 24 patients were excluded, leaving 79 participants for the study.

### *Data Collection:*

 Data collection involved retrospective and prospective evaluation of patients from the date of diagnosis until December 2021. Patients were monitored for the occurrence of aortopathy-related complications (acute aortic syndrome, indication for aortic surgery) and mortality.

### *Ethical Approval and Informed Consent:*

 This study received approval from the National Institute of Cardiology Research Ethics Committee (CAAE18868119.5.0000.5272), and all patients provided written informed consent.

### *Genetic analysis*

 Genetic analysis of NS-TAD patients was performed by targeted next-generation sequencing (tNGS) using a panel of 15 priority genes associated with aortic diseases (*ACTA2, COL3A1, FBN1, LOX, MFAP5, MYH11, MYLK, PRKG1, SMAD3, TGFB2, TGFBR1, TGFBR2, EFEMP2, SMAD2, FOXE3*) (13). Sequencing was performed using an Ion Torrent PGM platform (Thermo Fisher Scientific).

 Patients with clinical diagnosis (or suspect) of SMF were evaluated by direct sequencing of the coding regions of the FBN1 gene. Reads were compared with the RefSeq NG\_008805 using the Geneious Prime Software (Biomatters Ltd).

 Detailed information on DNA extraction, targeted next-generation sequencing Ion Torrent PGM (Thermo Fisher Scientific), direct Sanger sequencing are provided in the Supplementary Materials and Methods.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300140;](https://doi.org/10.1101/2023.12.22.23300140) this version posted December 26, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

#### *Variants classification*

 The variant call files (VCF) were subjected to a series of filters to exclude benign polymorphisms and intronic variants. These filters selected variants located in exons, splice 118 sites, and 3'/5' UTRs with sequencing coverage  $\geq$  20x and minor allele frequency (MAF) < 0.0005 in the general population (gnomAD, https://gnomad.broadinstitute.org/). Check of strand bias, indels in homopolymer and high frequency in internal samples were applied to detect and exclude false positives (sequencing artifacts). The remaining variants were classified according to the criteria set forth by the American College of Medical Genetics and Genomics (ACMG) and updates, and the Clinical Genome Resource (ClinGen) (14-17). Sequencing artifact suspects and clinical relevant variants were confirmed by direct sequencing. Reportable variants in this work were pathogenic variants (PV), likely pathogenic variants (LPV), and variants of uncertain significance (VUS).

### **RESULTS**

 We analyzed 79 individuals with TAD. The majority of patients presented a non- syndromic vascular phenotype; eight were diagnosed with MFS. Seventy-two patients were tested by tNGS and 7 MFS individuals were submitted to FBN1 direct sequencing screening. No variants were detected in EFEMP2, FOXE3, SMAD2 and TGFBR1. According to ACMG/AMP guidelines for variant classification we defined 5 PV, 5 LPV, and 19 VUS (Table 1 and 2). Sequencing artifacts and likely benign variants were excluded.

 The highest incidence of clinically relevant variants was found in the FBN1 gene, with 4 PV and 2 LPV (Figure 1), of these the majority of patients had MFS, and two presented with isolated aortopathy. The others PV/LPV were found once in each of the following genes: ACTA2, TGFB2R, MYLK, and SMAD3. Overall, there were 2 nonsense variants, four missense variants, two frameshift deletions, and two splice site variants. Six variants have been previously reported in association with MFS/TAA or cited in ClinVar database in an aorta disease case. We identified four novel variants in this cohort, of which the truncation variant p.Glu2019Ter in FBN1 was recently reported by our group in association with MFS (18). Hereafter, we detail each variant and the ACMG criteria used for pathogenicity classification.

### **FBN1**

 The missense variants in the FBN1 gene, p.Gly560Val and p.Arg1530Cys, were classified as pathogenic and likely pathogenic, respectively. The FBN1 gene is intolerant to missense variants as demonstrated by the gnomAD Z score value (5.06). Regarding missense variants are a common mechanism of pathogenicity for MFS and TAD (19,20), we applied the PP2 criterion to both variants. REVEL (Rare Variant Ensemble Leaner) score was used for in-silico effect prediction of rare missense variants according to Pejaver et al.

 (16). The variants p.Gly560Val and p.Arg1530Cys scored 0.945 and 0.871, which fit the 155 PP3 strong and PP3 moderate criteria, respectively. Detection of the p.Gly560Val confirmed the clinical diagnosis of SMF of patient AO94. The p.Arg1530Cys variant have been linked to MFS as well as TAD in various publications (21-29), however, the patient AO56, who carries it, experienced an aortic dissection at the age of 38y without an associated syndromic phenotype.

 The nonsense variant p.Arg429Ter in FBN1, identified in a female individual with MFS (AO45), is a known PV. Absent in the gnomAD database, the p.Arg429Ter variant has been reported in several individuals with MFS and has been found to segregate with the disease in families (30-34). This supports the application of PM2\_supporting, PS4\_Strong and PP1 criteria. The premature termination codon (PTC) generated by the variant is expected to lead to gene dysfunction through protein truncation or nonsense-mediated mRNA decay, which fills the PVS1 criterion.

### **TGFBR2**

 The missense variant c.1454G>A (p.Arg485His) in the Transforming Growth Factor-β receptor gene (TGFBR2) holds well-established clinical significance, being associated with individuals with SMF, LDS, and familial thoracic aortic dissection in multiple studies (35-40). Despite its high prevalence in affected individuals, the frequency of this variant in gnomAD is rare, which supports the application of criteria PS4 and PM2\_support, respectively. Additional gnomAD data indicates that the p.Arg485His variant is located in a hotspot region of the TGFBR2 gene, as all 18 VUS/PV described in ClinVar are confined to the region between exon 5 and 8 (PM1). Pannu et al. (36) reported the cosegregation of this variant with the phenotype of familial TAA and dissection with reduced penetrance in two unrelated families (PP1). The REVEL score for the p.Arg485His variant is 0.900, in line with the PP3\_moderate criterion. Due to the combined evidence from criteria PS4, PM1, PM2\_support, PP1, and PP3\_moderate, the p.Arg485His variant is classified as pathogenic.

 The variant was detected in a male patient (AO86) diagnosed at 48y with acute aortic syndrome, extracardiac affections (syndrome not diagnosed) and positive family history of cardiac death.

### **SMAD3**

 This gene is part of a group of genes recently associated with HTAD (41). The variant at the canonical splicing site (c.872-2A>G) in the SMAD3 gene results in loss of function of the gene product, which is an established mechanism of pathogenicity in SMAD3 (PVS1) (9,42). This variant is absent from gnomAD (PM2\_support) and has a single submission in ClinVar associated with TAA and dissection (PS4\_supporting). This PV (PVS1, PM2\_supporting and PS4\_supporting) was detected in a male patient diagnosed at the age of 35y with a 5.1 cm ascending aortic aneurysm.

## **ACTA2**

 The missense variant p.Arg314Gln (c.941G>A) in the ACTA2 gene has an annotation in ClinVar as a VUS in a TAA case, and is absent in population database (PM2\_supporting). The REVEL score of 0.939 indicates the PP3\_strong criterion. The ACTA2 gene is intolerant 198 to missense mutations (missense  $Z$  score = 3.2), and this type of mutation is a pathogenic mechanism in this gene, which fulfills the PP2 criterion. Due to the combination of PP3\_strong, PM2\_supporting, and PP2 criteria, the variant has been classified as likely pathogenic. The patient carrying this variant is female and has a positive family history. The diagnosis of TAA occurred at 48y, with an urgent surgical recommendation.

## **Novel variants:**

# **FBN1**

 The FBN1 variant c.1837+1G>C affects the canonical splicing site critical for proper mRNA processing. *In silico* evidence from ASSP (Alternative Splice Site Predictor) and Splice AI indicates the loss of the critical donor site, followed exon skipping and truncated 210 product formation (PVS1). The variant has not been reported in the gnomAD or ClinVar databases, neither in any publication (PM2\_support). On the other hand, two different variants at the same locus have been associated with fibrilinopathy/SMF (c.1837+1G>T [43]; c.1837+1G>A [44]). Thus, this variant has been classified as pathogenic based on the combination of PVS1, PM2\_support, and PS1 criteria. This variant was detected in a man diagnosed with ascending aortic dissection at 50y and positive family history of cardiac death.

217 The deletion c.7929 7930delTG in FBN1 alters the reading frame of the mRNA, resulting in a frameshift and generating a PTC, which is expected to lead to the absence of the gene product through nonsense-mediated decay (NMD) (15). This variant has not yet been reported in any publications or databases (PM2\_support). Therefore, based on the combination of PVS1 and PM2\_support criteria, we classified this variant as likely 222 pathogenic. The patient that harbors this variant is a female with MFS and aortic aneurysm diagnosed at 8y.

### **MYLK**

226 A frameshift deletion c.4848delG in the myosin light chain kinase gene (MYLK) has been classified as likely pathogenic based on the following criteria: PVS1 due to gene loss of 228 function through NMD; PM2 support due to absence in the gnomAD database. The patient with this variant is male, with a negative family history. He was diagnosed at 60y with TAA, requiring emergency surgery, and presenting with an ascending aorta diameter of 7.3 cm.

- 
- **Diagnosis yield**

 PV/LPV were identified in five patients out of 70 individuals with non-syndromic aortopathies resulting in an isolated aortopathy diagnosis rate of 7.1% through tNGS. The diagnostic yield for syndromic aortopathies (8 MFS and 1 undefined syndrome) cases was 55.5%, identifying five patients with PV/LPV.

- 
- **Variants of Uncertain Significance**
- 

 Nineteen VUS were detected in this cohort following the classification of reportable variants. Mutations of the following types were observed: missense (11), synonymous (5), 243 one frameshift deletion, and two SNV in UTR. Five variants are novel, and 14 variants have 244 already been reported in ClinVar. The majority of VUS were identified in the FBN1 (7) and MYLK (3) genes, followed by PRKG1 (2), MYH11 (2), and TGFβ2 (2), with one variant in the remaining genes: COL3A1, MFAP5, and LOX (Table 2).

 Two potentially pathogenic VUS in FBN1 were identified in individuals without PV/LPV. These variants did not meet the sufficient criteria for pathogenicity/benignity, due the insufficient available evidences at this time to determine the role of this variation in the disease. However, they stand out from other VUS by nearly reaching the required combination for classification as LPV.

 The variant p.Asp591Gly is located in the most missense-intolerant region of the FBN1 gene (O/E missense: 0.41). It has a low population frequency (0.000003980) in gnomAD database, with only one allele detected in the Latin/Amerindian population. We consider PM2\_suppoting for MAF<0.002% (45). The REVEL score indicates the PP3\_sup criterion. The combination of criteria PM1, PP2, PM2\_sup, and PP3\_sup for this VUS was insufficient to reach a level of pathogenicity. Patient AO42, who carries this mutation, has been diagnosed with aortic dissection at 48y and has a positive family history related to cardiac death.

 The VUS p.Ile1455Ser in the FBN1 gene also had only 1 allele found in gnomAD, but 261 it has already been reported in individuals with MFS/TAD in ClinVar and in a publication (46). 262 The REVEL score was compatible with PP3 mod. The carrier patient (AO88) was primarily diagnosed with ascending aortic aneurysm at the age of 58y.

### **DISCUSSION**

 TAD is a silent and highly morbid condition, and a prompt diagnosis and early intervention can save lives (47,48). Therefore, genetic screening becomes a significant tool for early identification, follow-up, and monitoring of high-risk patients, as well as for determining the course of action (48). In this study, a population with a TAD diagnosis age of ≤60 years was selected, given that this age group exhibits a lower incidence of sporadic TAD 272 (49). An average age of early clinical presentation was observed at  $44.6y$  ( $\pm$ 14.3), with a

 male predominance (63.3%) and 51.9% being of white ethnicity, consistent with observed in other studies (50-52).

 In the present study, targeted-Next Generation Sequencing (tNGS) was conducted to identify mutations in genes primarily associated with TAD in 71 patients from a tertiary cardiology hospital. A total of 29 reportable variants were identified, comprising 5 PV, 5 LPV, and 19 VUS. Among isolated aortopathies, our diagnostic yield was 7.1%. Other studies employing tNGS for the investigation of non-syndromic aortopathies reported a diagnostic yield of 4.9% for PV in 1025 patients analyzed (15 sequenced genes) (48) and 16.9% for PV/LPV in 32 genes analyzed (11). Despite the higher yield in the latter work in comparison of our results, SMAD2 was the only additional gene with mutations detected in Thoracic Aortic Aneurysm and Dissection (TAAD) (11).

 The above studies have shown that the majority of causal variant were detected in the 11 priority genes. The use of Whole Exome Sequencing (WES) in the investigation for aortopathies does not significantly increase the diagnostic yield of TAD, which generally does not reach 20%. Ziganshin et al. (53) performed WES on 102 TAAD patients and found deleterious variants in 3.9% of cases. Meanwhile, Wolford et al. (52) reported a 10.8% diagnostic yield when conducting WES in cases of aortic dissection or rupture. Yang et al. (54) achieved a diagnostic yield for NS-TAD of 18.7% using an investigative strategy that combined tNGS, MLPA, and WES, with WES adding only 3 individuals to the positive diagnosis group.

 Initial clinical suspicion is crucial for guiding genetic testing and achieving better diagnostic yield. In this study, patients with a diagnosis or suspicion of MSF were analyzed through direct sequencing of FBN1, resulting in a diagnostic yield of 50%. This yield is higher than that obtained by Renner et al. (11) with a multigene panel (29.8%) and lower than the 83.5% achieved with the combination of targeted Next-Generation Sequencing (tNGS), Multiplex Ligation-dependent Probe Amplification (MLPA), and Whole Exome Sequencing (WES) (53).

 Interpreting genetic sequencing data can be challenging due to variants exhibiting inconsistent characteristics for both pathogenicity and benignity (55). A guideline for interpreting genetic variants in aortopathies has not yet been established. Therefore, efforts dedicated to the careful classification of variants identified in patients with TAD can provide significant contributions to the interpretation and molecular diagnosis of these pathologies within the context of precision medicine (56).

 Ten PV/LPV were identified in 5 of the 15 analyzed genes (FBN1, ACTA2, TGFBR2, MYLK, and SMAD3), with four of these variants being reported in association with MFS/TAD for the first time in this study. FBN1 had the highest incidence, with six identified variants, following a similar pattern to other studies (57-59). Mutations in FBN1 were initially associated with MFS (60,61); subsequent studies revealed its association with Marfan-like syndromes (45,57). More recent studies have shown FBN1 variants related to NS-TAD, suggesting a common pathogenesis between NS-TAD and MFS (52,59,62). Cysteine

 substitutions in the calcium-binding of epidermal growth factor (EGF) like domains represent the majority of pathogenic missense changes associated with MFS (63). However, loss of function (LoF) variants were the principal type of variants discovered in our MFS cohort, followed by a glycine to valine substitution in the EGF-like 8 domain. One missense and one LoF variant were detected in non-syndromic aortopathies. Haploinsufficiency of fibrillin-1 is a pathogenic mechanism for both MFS (64,65) and NS-TAD (54). Missense mutations can also lead to decreased fibrillin secretion due to improper protein folding (66). In these cases, missense mutations and frameshift LoF mutations would share the haploinsufficiency mechanism.

 FBN1 was also prevalent in VUS (7). Of all VUS, only one (FBN1-p.Ile849Met) was found in an individual carrying a PV. On the other hand, two missense VUS identified in individuals with isolated aortopathies have the potential to be upgraded to LPV or PV. One of them (FBN1-p.Asp591Gly) is being reported for the first time in this study. The second VUS has previously been reported as an LPV for MFS (46); however, there is still a lack of evidence in the literature to define its burden. Reporting our findings will contribute to potentially elevating a VUS to a causal variant in the future. Investigating families could provide information lacking for the definitive association of VUS with the disease; unfortunately, we did not have access to the families in this study.

 In this study, PV/LPV were also found in the genes ACTA2, TGFBR2, MYLK, and SMAD3, for which gene-disease validity is definitive or strong for familial TAAD. Mutations in smooth muscle cell-specific genes (ACTA2, MYLK, MYH11) have been discovered in connection with familial TAAD. This characteristic typically exhibits autosomal dominant inheritance within families, with varying degrees of penetrance and expressivity (67). Actin alpha 2 is a highly conserved protein, and missense variants account for the majority of PV/LPV in this gene. The p.Arg314Gln variant is located in exon 7, the only one where no PV/LPV was annotated.

 We identified a novel frameshift variant (c.4848delG) in MYLK with the potential to disrupt protein function and result in loss of allele function through NMD. However, at this time, there is limited evidence to support the haploinsufficiency of this gene, given the limited number of TAAD-associated mutations in MYLK in the literature.

 Mutations in the TGFBR2 gene have previously been associated with LDS and TAAD in individuals with Marfanoid features (68,69). Patient AO86 exhibited syndromic features reported as EDS type, but without a conclusive diagnosis. The identified variant has a well- established association with TAD, with most studies reporting its association with isolated aortopathy. However, Law et al. (37) described carriers of the Arg485His variant with features overlapping EDS type 4 (OMIM 130050), such as soft translucent skin, arthralgia, and varicose veins, which could be considered a distinct syndrome.

 This investigation provides a comprehensive insight into aortopathies within a Brazilian cohort, highlighting the genetic diversity inherent in these conditions. The implementation of tNGS yielded a notable diagnostic rate, uncovering PV/LPV in genes

 associated with aortic diseases. The prevalence of mutations in the FBN1 gene, particularly among patients with both syndromic and non-syndromic Marfan-like features, underscores its clinical significance and underscores the necessity for an individualized approach in managing these cases. Furthermore, the identification of novel variants, whether associated with known syndromic phenotypes or not, contributes to the growing understanding of the genetic complexity of aortopathies. These findings underscore the importance of precise genetic screening as a fundamental tool for early intervention and personalized therapeutic strategies, paving the way for significant advancements toward precision medicine in the context of aortopathies.

## **Acknowledgments**

 The authors would like to thank the patients enrolled in this study and the support of INC and FAPERJ.

# **Author contributions**

 **JRF -** Conduction of the work, patient selection and recruitment, clinical evaluation, data collection and analysis, variant analysis, manuscript writing.

- **JPP –** Samples processing and NGS.
- **APAB** Samples processing and Sanger sequencing.
- **DNA** Analysis of NGS data and variants interpretation.
- **MMM –** Patients selection and recruitment, supervision of clinical evaluation.
- **HCVR –** Data analysis, study supervision.
- **GMD –** Study idealization, variant analysis, manuscript writing.
- 

## **Declaration of interests**

- 
- The authors declare no competing interests.
- 

### **REFERENCES**

- 
- 1. Faggion Vinholo T, Brownstein AJ, Ziganshin BA, Zafar MA, Kuivaniemi H, Body SC, et
- al. Genes Associated with Thoracic Aortic Aneurysm and Dissection: 2019 Update and Clinical Implications. Aorta (Stamford). 2019;07(04):099-107.
- 2. Sellke FW, Sellke FW, Coselli JS, Sundt TM, SpringerLink. Aortic dissection and acute aortic syndromes. 1st 2021. ed. Cham, Switzerland: Springer Nature Switzerland AG, 2021. 1 online resource (viii, 659 pages): illustrations p.
- 3. Centers for Disease Control and Prevention (CDC). Data and stats, aortic aneurysms. [About Multiple Cause of Death, 1999–2019.](https://wonder.cdc.gov/mcd-icd10.html) CDC WONDER Online Database website;
- 2021. https://www.cdc.gov/heartdisease/aortic\_aneurysm.htm, Accessed October 19,
- 2023.

 4. MS/SVS/CGIAE - Sistema de Informações sobre Mortalidade - SIM. Óbitos p/Residênc segundo Região 2020 [Available from: http://tabnet.datasus.gov.br/cgi/tabcgi.exe?sim/cnv/obt10uf.def.

- 5. Oladokun D, Patterson BO, Sobocinski J, Karthikesalingam A, Loftus I, Thompson MM, et al. Systematic Review of the Growth Rates and Influencing Factors in Thoracic Aortic Aneurysms. Eur J Vasc Endovasc Surg. 2016;51(5):674-81.
- 6. Guo, D. C. Regalado, E. S., Minn, C., Tran-Fadulu, V., Coney, J., Cao, J., Wang, M., Yu, R. K., Estrera, A.L., Safi, H. J., Shete, S. S., & Milewicz, D. M. (2011). Familial Thoracic Aortic Aneurysms and Dissections. *Circulation: Cardiovascular Genetics*, *4*(1), 36–42.
- 7. Fletcher AJ, Syed MBJ, Aitman TJ, Newby DE, Walker NL. Inherited Thoracic Aortic Disease: New Insights and Translational Targets. Circulation. 2020 May 12;141(19):1570-1587.
- 8. Ahmad MM, Kiani IA, Ammar KA, Ahmad MN, Khandheria BK, Paterick TE, et al. Ascending Aortic Aneurysm Is an Inherited Disease: A Contemporary Literature Review Based on Hill's Criteria of Specificity, Strength of Association, and Biological Coherence. Cardiol Rev. 2017;25(6):268-78.
- 9. Regalado ES, Guo DC, Villamizar C, Avidan N, Gilchrist D, McGillivray B, et al. Exome sequencing identifies SMAD3 mutations as a cause of familial thoracic aortic aneurysm and dissection with intracranial and other arterial aneurysms. Circ Res. 2011;109(6):680- 6.
- 10. Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases. Circ Res. 2019;124(4):588-606.
- 11. Renner S, Schüler H, Alawi M, Kolbe V, Rybczynski M, Woitschach R, Sheikhzadeh S, Stark VC, Olfe J, Roser E, Seggewies FS, Mahlmann A, Hempel M, Hartmann MJ, Hillebrand M, Wieczorek D, Volk AE, Kloth K, Koch-Hogrebe M, Abou Jamra R, Mitter D, Altmüller J, Wey-Fabrizius A, Petersen C, Rau I, Borck G, Kubisch C, Mir TS, von Kodolitsch Y, Kutsche K, Rosenberger G. Next-generation sequencing of 32 genes associated with hereditary aortopathies and related disorders of connective tissue in a cohort of 199 patients. Genet Med. 2019 Aug;21(8):1832-1841.
- 12. Verstraeten A, Alaerts M, Van Laer L, Loeys B. Marfan syndrome and related disorders: 25 years of gene discovery. Hum Mutat. 2016;37(6):524-31.
- 13. Renard M, Francis C, Ghosh R, Scott AF, Witmer PD, Adès LC, et al. Clinical Validity of Genes for Heritable Thoracic Aortic Aneurysm and Dissection. J Am Coll Cardiol. 2018;72(6):605-15.
- 14. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.
- 15. Abou Tayoun et al., Pesaran T, DiStefano MT, Oza A, Rehm HL, Biesecker LG, Harrison SM; ClinGen Sequence Variant Interpretation Working Group (ClinGen SVI).

 Recommendations for interpreting the loss of function PVS1 ACMG/AMP variant criterion. Hum Mutat. 2018 Nov;39(11):1517-1524.

- 16. Pejaver V, Byrne AB, Feng BJ, Pagel KA, Mooney SD, Karchin R, O'Donnell-Luria A, Harrison SM, Tavtigian SV, Greenblatt MS, Biesecker LG, Radivojac P, Brenner SE; ClinGen Sequence Variant Interpretation Working Group. Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criterion. Am J Hum Genet. 2022 Dec 1;109(12):2163-2177.
- 17. Walker LC, de la Hoya M, Wiggins GAR, Lindy A, Vincent LM, Parsons MT, Canson DM,
- Bis-Brewer D, Cass A, Tchourbanov A, Zimmermann H, Byrne AB, Pesaran T, Karam R, Harrison S, Spurdle AB. Application of the ACMG/AMP framework to capture evidence relevant to predicted and observed impact on splicing: recommendations from the clingen svi splicing subgroup. medRxiv [Preprint]. 2023 Feb 26:2023.02.24.23286431. Update in: Am J Hum Genet. 2023 Jun
- 18. Pereira JP, Ferreira JR, Botelho APA, Melo MM, Dias GM. Identification of a novel pathogenic variant in FBN1 associated with Marfan Syndrome. Cold Spring Harb Mol Case Stud. 2022 May 19;8(4):a006215.
- 19. Ghosh R, Oak N, Plon SE. Evaluation of in silico algorithms for use with ACMG/AMP clinical variant interpretation guidelines. Genome Biol. 2017 Nov 28;18(1):225.
- 20. Sakai LY, Keene DR, Renard M, De Backer J. FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene. 2016 Oct 10;591(1):279-291.
- 21. Jin C, Yao K, Jiang J, Tang X, Shentu X, Wu R. Novel FBN1 mutations associated with predominant ectopia lentis and marfanoid habitus in Chinese patients. Mol Vis. 2007 Jul 24; 13:1280-4.
- 22. Aragon-Martin JA, Ahnood D, Charteris DG, Saggar A, Nischal KK, Comeglio P, Chandra A, Child AH, Arno G. Role of ADAMTSL4 mutations in FBN1 mutation-negative ectopia lentis patients. Hum Mutat. 2010 Aug;31(8):E1622-31.
- 23. Biggin A, Holman K, Brett M, Bennetts B, Adès L. Detection of thirty novel FBN1 mutations in patients with Marfan syndrome or a related fibrillinopathy. Hum Mutat. 2004 Jan;23(1):99.
- 24. Howarth R, Yearwood C, Harvey JF. Application of dHPLC for mutation detection of the fibrillin-1 gene for the diagnosis of Marfan syndrome in a National Health Service Laboratory. Genet Test. 2007 Summer;11(2):146-52.
- 25. Loeys B, Nuytinck L, Delvaux I, De Bie S, De Paepe A. Genotype and phenotype analysis of 171 patients referred for molecular study of the fibrillin-1 gene FBN1 because of suspected Marfan syndrome. Arch Intern Med. 2001 Nov 12;161(20):2447-54.
- 26. Rand-Hendriksen S, Tjeldhorn L, Lundby R, Semb SO, Offstad J, Andersen K, Geiran O, Paus B. Search for correlations between FBN1 genotype and complete Ghent phenotype in 44 unrelated Norwegian patients with Marfan syndrome. Am J Med Genet A. 2007 Sep 1;143A(17):1968-77.

27. Villamizar C, Regalado ES, Fadulu VT, Hasham SN, Gupta P, Willing MC, Kuang SQ,

Guo D, Muilenburg A, Yee RW, Fan Y, Towbin J, Coselli JS, LeMaire SA, Milewicz DM.

- Paucity of skeletal manifestations in Hispanic families with FBN1 mutations. Eur J Med
- Genet. 2010 Mar-Apr;53(2):80-4.
- 28. Wang WJ, Han P, Zheng J, Hu FY, Zhu Y, Xie JS, Guo J, Zhang Z, Dong J, Zheng GY, Cao H, Liu TS, Fu Q, Sun L, Yang BB, Tian XL. Exon 47 skipping of fibrillin-1 leads preferentially to cardiovascular defects in patients with thoracic aortic aneurysms and dissections. J Mol Med (Berl). 2013 Jan;91(1):37-47.
- 29. Yoo EH, Woo H, Ki CS, Lee HJ, Kim DK, Kang IS, Park P, Sung K, Lee CS, Chung TY,
- Moon JR, Han H, Lee ST, Kim JW. Clinical and genetic analysis of Korean patients with Marfan syndrome: possible ethnic differences in clinical manifestation. Clin Genet. 2010 Feb;77(2):177-82.
- 30. Rommel K, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M. Mutation screening of the fibrillin-1 (FBN1) gene in 76 unrelated patients with Marfan syndrome or Marfanoid features leads to the identification of 11 novel and three previously reported mutations. Hum Mutat. 2002 Nov;20(5):406-7.
- 31. Sakai H, Visser R, Ikegawa S, Ito E, Numabe H, Watanabe Y, Mikami H, Kondoh T, Kitoh H, Sugiyama R, Okamoto N, Ogata T, Fodde R, Mizuno S, Takamura K, Egashira M, Sasaki N, Watanabe S, Nishimaki S, Takada F, Nagai T, Okada Y, Aoka Y, Yasuda K, Iwasa M, Kogaki S, Harada N, Mizuguchi T, Matsumoto N. Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes. Am J Med Genet A. 2006 Aug 15;140(16):1719-25.
- 32. Attanasio M, Lapini I, Evangelisti L, Lucarini L, Giusti B, Porciani M, Fattori R, Anichini C, Abbate R, Gensini G, Pepe G. FBN1 mutation screening of patients with Marfan syndrome and related disorders: detection of 46 novel FBN1 mutations. Clin Genet. 2008 Jul;74(1):39-46.
- 33. Magyar I, Colman D, Arnold E, Baumgartner D, Bottani A, Fokstuen S, Addor MC, Berger W, Carrel T, Steinmann B, Mátyás G. Quantitative sequence analysis of FBN1 premature termination codons provides evidence for incomplete NMD in leukocytes. Hum Mutat. 2009 Sep;30(9):1355-64.
- 34. Yang H, Luo M, Chen Q, Fu Y, Zhang J, Qian X, Sun X, Fan Y, Zhou Z, Chang Q. Genetic testing of the FBN1 gene in Chinese patients with Marfan/Marfan-like syndrome. Clin Chim Acta. 2016 Aug 1;459:30-35.
- 35. Disabella E, Grasso M, Marziliano N, Ansaldi S, Lucchelli C, Porcu E, Tagliani M, Pilotto A, Diegoli M, Lanzarini L, Malattia C, Pelliccia A, Ficcadenti A, Gabrielli O, Arbustini E. Two novel and one known mutation of the TGFBR2 gene in Marfan syndrome not associated with FBN1 gene defects. Eur J Hum Genet. 2006 Jan;14(1):34-8.
- 36. Pannu H, Fadulu VT, Chang J, Lafont A, Hasham SN, Sparks E, Giampietro PF, Zaleski C, Estrera AL, Safi HJ, Shete S, Willing MC, Raman CS, Milewicz DM. Mutations in

 transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation. 2005 Jul 26;112(4):513-20.

- 37. Law C, Bunyan D, Castle B, Day L, Simpson I, Westwood G, Keeton B. Clinical features in a family with an R460H mutation in transforming growth factor beta receptor 2 gene. J Med Genet. 2006 Dec;43(12):908-16.
- 38. Campens L, Callewaert B, Muiño Mosquera L, Renard M, Symoens S, De Paepe A, Coucke P, De Backer J. Gene panel sequencing in heritable thoracic aortic disorders and related entities - results of comprehensive testing in a cohort of 264 patients. Orphanet J Rare Dis. 2015 Feb 3;10:9.
- 39. Singh KK, Rommel K, Mishra A, Karck M, Haverich A, Schmidtke J, Arslan-Kirchner M. TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome. Hum Mutat. 2006 Aug;27(8):770-7.
- 40. Guerrerio AL, Frischmeyer-Guerrerio PA, Huang C, Wu Y, Haritunians T, McGovern DPB, MacCarrick GL, Brant SR, Dietz HC. Increased Prevalence of Inflammatory Bowel Disease in Patients with Mutations in Genes Encoding the Receptor Subunits for TGFβ. Inflamm Bowel Dis. 2016 Sep;22(9):2058-2062.
- 41. Takeda N, Komuro I. Genetic basis of hereditary thoracic aortic aneurysms and dissections. J Cardiol. 2019 Aug;74(2):136-143.
- 42. Aubart M, Gobert D, Aubart-Cohen F, Detaint D, Hanna N, d'Indya H, Lequintrec JS, Renard P, Vigneron AM, Dieudé P, Laissy JP, Koch P, Muti C, Roume J, Cusin V, Grandchamp B, Gouya L, LeGuern E, Papo T, Boileau C, Jondeau G. Early-onset osteoarthritis, Charcot-Marie-Tooth like neuropathy, autoimmune features, multiple arterial aneurysms and dissections: an unrecognized and life threatening condition. PLoS One. 2014 May 7;9(5):e96387.
- 43. Stheneur C, Collod-Béroud G, Faivre L, Buyck JF, Gouya L, Le Parc JM, Moura B, Muti C, Grandchamp B, Sultan G, Claustres M, Aegerter P, Chevallier B, Jondeau G, Boileau C. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet. 2009 Sep;17(9):1121-8.
- 44. Loeys B, De Backer J, Van Acker P, Wettinck K, Pals G, Nuytinck L, Coucke P, De Paepe A. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat. 2004 Aug;24(2):140-6.
- 45. Harrison SM, Biesecker LG, Rehm HL. Overview of Specifications to the ACMG/AMP Variant Interpretation Guidelines. Curr Protoc Hum Genet. 2019 Sep;103(1):e93.
- 46. Lerner-Ellis JP, Aldubayan SH, Hernandez AL, Kelly MA, Stuenkel AJ, Walsh J, Joshi VA. The spectrum of FBN1, TGFβR1, TGFβR2 and ACTA2 variants in 594 individuals with suspected Marfan Syndrome, Loeys-Dietz Syndrome or Thoracic Aortic Aneurysms and Dissections (TAAD). Mol Genet Metab. 2014 Jun;112(2):171-6.
- 47. Johansson G, Markstrom U, Swedenborg J. Ruptured thoracic aortic aneurysms: a study of incidence and mortality rates. J Vasc Surg. 1995;21(6):985-8.

 48. Weerakkody R, Ross D, Parry DA, Ziganshin B, Vandrovcova J, Gampawar P, Abdullah A, Biggs J, Dumfarth J, Ibrahim Y; Yale Aortic Institute Data and Repository Team; Bicknell C, Field M, Elefteriades J, Cheshire N, Aitman TJ. Targeted genetic analysis in a large cohort of familial and sporadic cases of aneurysm or dissection of the thoracic aorta. Genet Med. 2018 Nov;20(11):1414-1422.

- 49. Isselbacher EM, Preventza O, Hamilton Black J 3rd, Augoustides JG, Beck AW, Bolen MA, Braverman AC, Bray BE, Brown-Zimmerman MM, Chen EP, Collins TJ, DeAnda A Jr, Fanola CL, Girardi LN, Hicks CW, Hui DS, Schuyler Jones W, Kalahasti V, Kim KM, Milewicz DM, Oderich GS, Ogbechie L, Promes SB, Gyang Ross E, Schermerhorn ML, Singleton Times S, Tseng EE, Wang GJ, Woo YJ. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Dec 13;146(24):e334-e482.
- 50. Trimarchi S, Nienaber CA, Rampoldi V, Myrmel T, Suzuki T, Mehta RH, et al. Contemporary results of surgery in acute type A aortic dissection: The International Registry of Acute Aortic Dissection experience. J Thorac Cardiovasc Surg. 2005;129(1):112-22.
- 51. Sherrah AG, Andvik S, van der Linde D, Davies L, Bannon PG, Padang R, et al. Nonsyndromic Thoracic Aortic Aneurysm and Dissection: Outcomes With Marfan Syndrome Versus Bicuspid Aortic Valve Aneurysm. J Am Coll Cardiol. 2016;67(6):618- 26.
- 52. Wolford BN, Hornsby WE, Guo D, Zhou W, Lin M, Farhat L, et al. Clinical Implications of Identifying Pathogenic Variants in Individuals With Thoracic Aortic Dissection. Circ Genom Precis Med. 2019;12(6):e002476.
- 53. Ziganshin BA, Bailey AE, Coons C, Dykas D, Charilaou P, Tanriverdi LH, et al. Routine Genetic Testing for Thoracic Aortic Aneurysm and Dissection in a Clinical Setting. Ann Thorac Surg. 2015;100(5):1604-11.
- 54. Yang H, Shen H, Zhu G, Shao X, Chen Q, Yang F, Zhang Y, Zhang Y, Zhao K, Luo M, Zhou Z, Shu C. Molecular characterization and clinical investigation of patients with heritable thoracic aortic aneurysm and dissection. J Thorac Cardiovasc Surg. 2022 Nov 12:S0022-5223(22)01234-X.
- 55. Koboldt, D.C. Best practices for variant calling in clinical sequencing. *Genome Med* 12, 91 (2020).
- 56. Ponińska JK, Bilińska ZT, Truszkowska G, Michalak E, Podgórska A, Stępień-Wojno M, Chmielewski P, Lutyńska A, Płoski R. Good performance of the criteria of American College of Medical Genetics and Genomics/Association for Molecular Pathology in prediction of pathogenicity of genetic variants causing thoracic aortic aneurysms and dissections. J Transl Med. 2022 Jan 25;20(1):42.

 57. Wooderchak-Donahue W, VanSant-Webb C, Tvrdik T, Plant P, Lewis T, Stocks J, et al. Clinical utility of a next generation sequencing panel assay for Marfan and Marfan-like syndromes featuring aortopathy. Am J Med Genet A. 2015;167A(8):1747-57.

- 58. Poninska JK, Bilinska ZT, Franaszczyk M, Michalak E, Rydzanicz M, Szpakowski E, et al. Next-generation sequencing for diagnosis of thoracic aortic aneurysms and dissections: diagnostic yield, novel mutations and genotype phenotype correlations. J Transl Med. 2016;14(1):115.
- 59. Proost D, Vandeweyer G, Meester JA, Salemink S, Kempers M, Ingram C, et al. Performant mutation identification using targeted next-generation sequencing of 14 thoracic aortic aneurysm genes. Hum Mutat. 2015;36(8):808-14.
- 60. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337-9.
- 61. Maslen CL, Corson GM, Maddox BK, Glanville RW, Sakai LY. Partial sequence of a candidate gene for the Marfan syndrome. Nature. 1991;352(6333):334-7.
- 62. Fang M, Yu C, Chen S, Xiong W, Li X, Zeng R, et al. Identification of Novel Clinically Relevant Variants in 70 Southern Chinese patients with Thoracic Aortic Aneurysm and Dissection by Next-generation Sequencing. Sci Rep. 2017;7(1):10035.
- 63. Collod-Béroud G, Le Bourdelles S, Ades L, Ala-Kokko L, Booms P, Boxer M, Child A, Comeglio P, De Paepe A, Hyland JC, Holman K, Kaitila I, Loeys B, Mátyás G, Nuytinck L, Peltonen L, Rantamaki T, Robinson P, Steinmann B, Junien C, Béroud C, Boileau C. Update of the UMD-FBN1 mutation database and creation of an FBN1 polymorphism database. Hum Mutat. 2003 Sep;22(3):199-208.
- 64. Mátyás G, Alonso S, Patrignani A, Marti M, Arnold E, Magyar I, Henggeler C, Carrel T, Steinmann B, Berger W. Large genomic fibrillin-1 (FBN1) gene deletions provide evidence for true haploinsufficiency in Marfan syndrome. Hum Genet. 2007 Aug;122(1):23-32.
- 65. Li J, Wu W, Lu C, Liu Y, Wang R, Si N, Liu F, Zhou J, Zhang S, Zhang X. Gross deletions in FBN1 results in variable phenotypes of Marfan syndrome. Clin Chim Acta. 2017 Nov;474:54-59.
- 66. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid Redox Signal. 2006;8:338–346.
- 67. Albornoz G, Coady MA, Roberts M, Davies RR, Tranquilli M, Rizzo JA, Elefteriades JA. Familial thoracic aortic aneurysms and dissections--incidence, modes of inheritance, and phenotypic patterns. Ann Thorac Surg. 2006 Oct;82(4):1400-5.
- 68. Loeys BL, Chen J, Neptune ER, et al. A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005;37:275–281.

perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.12.22.23300140;](https://doi.org/10.1101/2023.12.22.23300140) this version posted December 26, 2023. The copyright holder for this<br>preprint (which was not certified by peer review) is the author/funder, who has grante

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

- 626 69. Mizuguchi T, Collod-Beroud G, Akiyama T, et al. Heterozygous TGFBR2 mutations in
- 627 Marfan syndrome. Nat Genet. 2004;36:855–860.

## **FIGURE LEGEND**

- 
- 

 **Figure 1** – Structure of the FBN1 gene representing the respective domains of the fibrillin-1 protein. The six VP/VPP identified in the FBN1 gene are pointed. EGF: epidermal growth factor-like domains; cb-EGF: EGF-like domains with a calcium-binding domain; TB domain: domains similar to TGF-b binding proteins; hybrid: hybrid containing characteristics of the TB and cb-EGF domains

**TABLES** 

### **Table 1. Pathogenic and likely pathogenic variants**



ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

<sup>a</sup>FBN1 direct sequencing approach

b Variant reported in several people with MFS (PMID: 12402346, 18435798, 16835936, 27234404, 19618372)

c Variant reported cosegregation with disease in affected family members (PMID: 12402346, 16835936, 18435798)

d Variant associated with SMF in 5 non-related people (PMID: 14695540, 17627385, 17663468, 11700157)

<sup>e</sup>Parents are not variant carriers without paternity confirmation

f Pathogenic variants with another nucleotide exchange at the same splice site +-1,2 (c.1837+1G>A/T, PMID: 19293843, 15241795)

 $\mathrm{^{g}}$ Variant reported in several people with aortopathies (PMID: 16027248, 16885183, 25644172, 27508510, 23884466, 18852674)

<sup>h</sup>Variant segregates with aortopathies in some families (PMID: 16027248, 16885183)

i Variant reported in 2 MFS individuals in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/803096/) j Variant reported in 1 MFS individuals in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/1968962/)

## **Table 2. Variants of uncertain significance**



ACMG, American College of Medical Genetic and Genomic; ID, subject identification; MAF, minor allele frequency in gnomAD; NR, not reported; EC, extracardiac affections; str, strong; mod, moderate; sup, supporting

<sup>a</sup>FBN1 direct sequencing approach

